1. Home
  2. ARVN vs AIP Comparison

ARVN vs AIP Comparison

Compare ARVN & AIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARVN
  • AIP
  • Stock Information
  • Founded
  • ARVN 2015
  • AIP 2003
  • Country
  • ARVN United States
  • AIP United States
  • Employees
  • ARVN 430
  • AIP N/A
  • Industry
  • ARVN Biotechnology: Pharmaceutical Preparations
  • AIP Semiconductors
  • Sector
  • ARVN Health Care
  • AIP Technology
  • Exchange
  • ARVN Nasdaq
  • AIP Nasdaq
  • Market Cap
  • ARVN 676.2M
  • AIP 579.6M
  • IPO Year
  • ARVN 2018
  • AIP 2021
  • Fundamental
  • Price
  • ARVN $9.45
  • AIP $14.20
  • Analyst Decision
  • ARVN Buy
  • AIP Strong Buy
  • Analyst Count
  • ARVN 23
  • AIP 3
  • Target Price
  • ARVN $17.61
  • AIP $15.00
  • AVG Volume (30 Days)
  • ARVN 2.6M
  • AIP 897.5K
  • Earning Date
  • ARVN 11-04-2025
  • AIP 11-04-2025
  • Dividend Yield
  • ARVN N/A
  • AIP N/A
  • EPS Growth
  • ARVN N/A
  • AIP N/A
  • EPS
  • ARVN N/A
  • AIP N/A
  • Revenue
  • ARVN $372,800,000.00
  • AIP $63,236,000.00
  • Revenue This Year
  • ARVN $1.01
  • AIP $19.05
  • Revenue Next Year
  • ARVN N/A
  • AIP $17.96
  • P/E Ratio
  • ARVN N/A
  • AIP N/A
  • Revenue Growth
  • ARVN 299.57
  • AIP 18.64
  • 52 Week Low
  • ARVN $5.90
  • AIP $5.46
  • 52 Week High
  • ARVN $29.61
  • AIP $14.88
  • Technical
  • Relative Strength Index (RSI)
  • ARVN 57.54
  • AIP 61.87
  • Support Level
  • ARVN $9.01
  • AIP $12.35
  • Resistance Level
  • ARVN $9.55
  • AIP $14.60
  • Average True Range (ATR)
  • ARVN 0.49
  • AIP 0.98
  • MACD
  • ARVN -0.10
  • AIP -0.01
  • Stochastic Oscillator
  • ARVN 44.37
  • AIP 73.12

About ARVN Arvinas Inc.

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

About AIP Arteris Inc.

Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.

Share on Social Networks: